X
[{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase I"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rejuvenate Biomed Announces Positive Results from Phase 1b Clinical Trial with RJx-01 in Sarcopenia","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"},{"orgOrder":0,"company":"Rejuvenate Biomed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rejuvenate Bio Announces Preclinical Data for Gene Therapy Candidate RJB-0402 for the Treatment of Arrhythmogenic Cardiomyopathy","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Rejuvenate Biomed
Filters
Companies By Therapeutic Area
Details:
RJB-0402 is a liver-targeting adeno-associated virus vector-based gene therapy that drives over expression of FGF21, which is investigated for the treatment of arrhythmogenic cardiomyopathy.
Lead Product(s):
RJB-0402
Therapeutic Area: Genetic Disease
Product Name: RJB-0402
Highest Development Status: Preclinical
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 09, 2023
Details:
RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.
Lead Product(s):
Galanthamine ,Metformin
Therapeutic Area: Musculoskeletal
Product Name: RJx-01
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 04, 2023
Details:
RJx-01 is a novel combination of known drugs, there are already extensive safety data available for the constituent compounds. Results will be based on a combination of classic and hi-tech assessment techniques, including data from wearable health tech devices.
Lead Product(s):
RJx-01
Therapeutic Area: Genetic Disease
Product Name: RJx-01
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 29, 2022